142 related articles for article (PubMed ID: 8578508)
1. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1995 Jul; 74(1):464-72. PubMed ID: 8578508
[No Abstract] [Full Text] [Related]
2. Thrombin functions and antithrombotic intervention.
Fenton JW
Thromb Haemost; 1995 Jul; 74(1):493-8. PubMed ID: 8578512
[No Abstract] [Full Text] [Related]
3. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
Verstraete M
Thromb Haemost; 1997 Jul; 78(1):357-63. PubMed ID: 9198179
[No Abstract] [Full Text] [Related]
4. In the bivalirudin era, are we still looking for a potent antiplatelet agent?
Cortese B; Pitì A; Kastrati A; Sibbing D
Curr Vasc Pharmacol; 2012 Jul; 10(4):476-8. PubMed ID: 22339254
[TBL] [Abstract][Full Text] [Related]
5. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Reginelli JP; Chew D
J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809
[No Abstract] [Full Text] [Related]
6. Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin.
White HD
Am Heart J; 2002 Feb; 143(2):189-92. PubMed ID: 11835018
[No Abstract] [Full Text] [Related]
7. Bivalirudin: the relevance in today's interventional practice.
Jariwala P; Chandra KS
Indian Heart J; 2012; 64(5):449-52. PubMed ID: 23102381
[No Abstract] [Full Text] [Related]
8. Advances in antithrombotic therapy: novel agents.
Turpie AG; Weitz JI; Hirsh J
Thromb Haemost; 1995 Jul; 74(1):565-71. PubMed ID: 8578525
[TBL] [Abstract][Full Text] [Related]
9. Platelet resistance - much known and much more unknown.
Dieter RS; Lopez JJ; Nanjundappa A
J Invasive Cardiol; 2011 Jan; 23(1):14. PubMed ID: 21183764
[No Abstract] [Full Text] [Related]
10. Clinical trials of conjunctive anticoagulant strategies in thrombolysis.
Kleiman NS
Coron Artery Dis; 1996 Jul; 7(7):508-15. PubMed ID: 8913678
[No Abstract] [Full Text] [Related]
11. [The HEAT-PPCI study].
Saia F; Dall'Ara G; Calabrò P
G Ital Cardiol (Rome); 2015 Feb; 16(2):65-70. PubMed ID: 25805088
[No Abstract] [Full Text] [Related]
12. [Direct thrombin antagonists].
Lankes W; Fleischer K; Gulba DC
Herz; 2001 Apr; 26 Suppl 1():46-52. PubMed ID: 11349627
[TBL] [Abstract][Full Text] [Related]
13. FDA panel votes against approval for bivalirudin.
Piña I
Circulation; 1999 Mar; 99(10):1277. PubMed ID: 10077507
[No Abstract] [Full Text] [Related]
14. Publication policy, informed consent, and the randomized clinical trial.
Califf RM
Am Heart J; 2002 Feb; 143(2):187-8. PubMed ID: 11835017
[No Abstract] [Full Text] [Related]
15. An overview of antithrombins in peripheral vascular interventions.
Shammas NW
J Invasive Cardiol; 2004 Aug; 16(8):440-3. PubMed ID: 15282423
[No Abstract] [Full Text] [Related]
16. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.
Callas D; Fareed J
Thromb Haemost; 1995 Jul; 74(1):473-81. PubMed ID: 8578509
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin (Angiomax) for angioplasty.
Med Lett Drugs Ther; 2001 Apr; 43(1103):37-8. PubMed ID: 11331441
[No Abstract] [Full Text] [Related]
19. The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation.
Schneider DJ
J Invasive Cardiol; 2004 Dec; 16 Suppl G():8-11. PubMed ID: 23570202
[TBL] [Abstract][Full Text] [Related]
20. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
